摘要
Abstract
Objective:To observe the clinical efficacy of Recombinant Human Growth Hormone (rhGH) in treatment of idiopathic short stature (ISS) and growth hormone deficiency (GHD).Method:A total of 30children with ISS and GHD treated in our hospital from May 2014 to October 2016 were selected as ISS group and GHD group respectively.Both groups were subcutaneously injected with the same dose of rhGH 30 minutes before bedtime for 12 months.The growth and development indicators (height, body mass index, growth rate and bone age) and biochemical indicators (FPG, IGF-1, IGFBP-3) before and after treatment, and incidence of adverse reactions between two groups were compared.Result:After treatment, the height, growth rate, bone age, IGF-1 and IGFBP-3 of two groups were higher than those of before treatment, and GHD group were higher than those of ISS group, the differences were statistically significant (P<0.05).But after treatment, the body mass index and FPG of two groups were compared, the differences were not statistically significant (P>0.05).The incidence of adverse reactions in GHD group was 6.67％lower than 26.67％in ISS group (P<0.05).Conclusion:Compared with ISS, the growth and development recovery of GHD patients after rhGH treatment is more obvious, the incidence of complications is lower, and the safety is better.关键词
重组人生长激素/特发性矮小症/生长激素缺乏症/儿童Key words
Recombinant Human Growth Hormone/Idiopathic short stature/Growth hormone deficiency/Children
